Lume-meso: A double-blind, randomized, phase II/III study of nintedanib (N) + pemetrexed (P)/cisplatin (C) followed by maintenance N versus placebo + P/C followed by maintenance placebo for patients ...
This study looked at ways to improve the quality of life of people with mesothelioma of the chest (pleural mesothelioma). This study was open for people to join between April 2014 and October 2016.
Peter Szlosarek, Professor of Medical Oncology at Queen Mary's Barts Cancer Institute, presented his team’s results from the ATOMIC-Meso clinical trial in partnership with Polaris Pharmaceuticals, Inc ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. In a recent update, NovoCure Ltd.
A cancer diagnosis is never good news – and a diagnosis of malignant mesothelioma may be the worst news of all. However, an innovative therapy, developed by Professor Peter Szlosarek and his team in ...
Hemi-thoracic irradiation with proton therapy in malignant pleural Mesothelioma (HIT-Meso) sub-study
HIT-Meso is a clinical trial led by Consultant Clinical Oncologist, Dr Crispin Hiley and based at the UCL Cancer Institute. You can see details of the main clinical trial on the UCL website. HIT-Meso ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results